Hims vs Henry Meds 2026: GLP-1 Weight Loss Programs Compared

Head-to-Head Comparison Table

The following table compares Hims, Henry Meds, and Trimi across the factors that matter most for patients choosing a GLP-1 weight loss provider. All pricing reflects data observed in early 2026.

Pricing Comparison: Where Your Money Actually Goes

Pricing is the primary reason patients compare Hims and Henry Meds, and the differences are significant when you look beyond the headline numbers. GLP-1 therapy is not a one-month commitment — most patients need 6 to 12 months of continuous treatment to reach their weight loss goals, and many continue maintenance dosing beyond that. Monthly cost differences that seem modest in isolation compound into hundreds or thousands of dollars over a treatment course.

Hims prices compounded semaglutide between approximately $149 and $199 per month depending on dose tier. Their tirzepatide pricing ranges from $199 to $299 per month. Consultations are included in the plan cost, and Hims does not charge a separate evaluation fee. This bundled approach simplifies the cost calculation but the monthly rate itself is higher than some competitors for the medication alone.

Henry Meds prices compounded semaglutide between approximately $199 and $349 per month, with tirzepatide ranging from $299 to $449 per month. Additionally, Henry Meds charges a separate consultation fee of $49 to $99 for initial provider evaluations. This means a new Henry Meds patient starting semaglutide could pay $248 to $448 in their first month before any medication arrives. Over 12 months, this cost structure adds up substantially.

At Trimi, compounded semaglutide costs $99 per month and compounded tirzepatide costs $125 per month. There is no consultation fee, no enrollment fee, and no contract. A patient taking semaglutide for 12 months at Trimi pays $1,188 total. The same patient at Hims pays $1,788 to $2,388. At Henry Meds, that figure climbs to $2,388 to $4,188 — meaning the annual difference between Trimi and Henry Meds can exceed $3,000. For patients weighing the cheapest GLP-1 options in 2026, this gap is difficult to ignore.

Medications and Access: What Each Platform Offers

Both Hims and Henry Meds prescribe compounded versions of the two most clinically proven GLP-1 weight loss medications: semaglutide and tirzepatide. The active ingredients are identical to those in the brand-name products Wegovy, Ozempic, Zepbound, and Mounjaro. Compounded medications are prepared by accredited pharmacies under FDA-regulated conditions, and the pharmacological effect is the same regardless of which telehealth platform facilitates the prescription.

Hims offers both compounded semaglutide and compounded tirzepatide, though tirzepatide availability has varied over time depending on regulatory conditions and pharmacy capacity. Their platform distributes medications through an established network of compounding pharmacy partners built over years of operating across multiple health categories. Hims delivers medications via their app-based system, with patients managing refills and dose adjustments through the platform.

Henry Meds similarly offers both compounded semaglutide and compounded tirzepatide. As a more focused platform, Henry Meds has built pharmacy relationships specifically around weight loss medications. Their web-based system handles prescriptions and refills, with medications shipped directly to the patient. Henry Meds has occasionally offered additional compounded formulations or combination products, though availability fluctuates.

Trimi offers both compounded semaglutide and compounded tirzepatide as core offerings with consistent availability. Because Trimi focuses specifically on metabolic health and GLP-1 therapy, medication supply continuity is a central operational priority rather than one product line among many. Patients who start with semaglutide and later want to transition to tirzepatide — or vice versa based on response and tolerability — can do so seamlessly within the same platform and provider relationship.

Provider Experience: Comparing Telehealth Models

The provider experience is where Hims and Henry Meds differ most meaningfully, and it is an aspect that many patients underweight when choosing a GLP-1 platform. GLP-1 therapy involves dose titration decisions, side effect management, treatment duration planning, and ongoing clinical monitoring — all of which benefit from provider expertise and engagement.

Hims operates primarily through an app-based asynchronous model. Patients complete an online health questionnaire, a provider reviews the submission, and if appropriate, a prescription is issued without a live consultation. This approach is fast and convenient — many patients receive prescriptions within 24 to 48 hours. The trade-off is limited clinical dialogue. When you have questions about side effects, want to discuss dose adjustments, or need guidance on managing semaglutide side effects like nausea or constipation, the asynchronous model can feel impersonal. Hims providers cover dozens of health categories, meaning the provider reviewing your weight loss case may also be handling dermatology and mental health cases throughout the same shift.

Henry Meds uses a web-based consultation system that may include more direct interaction during the initial evaluation phase. Some Henry Meds plans include video consultations or phone calls with providers, which allows for more clinical dialogue than a questionnaire-only model. However, Henry Meds charges separately for this consultation access — the $49 to $99 initial consultation fee reflects the added provider time. Ongoing provider interactions vary by plan and may diminish after the initial prescription.

Trimi's provider model centers on clinicians who focus specifically on weight management and metabolic health. This specialization matters for GLP-1 therapy because effective dose titration, side effect mitigation, and long-term treatment planning benefit from providers who manage these cases daily rather than occasionally. Trimi's web and messaging-based system allows patients to communicate directly with their care team for dose questions, side effect guidance, and treatment adjustments without additional fees.

Clinical Evidence: The Medication Drives Results, Not the Platform

A critical point that sometimes gets lost in provider comparisons: your weight loss outcomes are determined by the medication, the dose, and your adherence to treatment — not which telehealth brand delivered the prescription. The clinical evidence supporting GLP-1 medications for weight loss is extensive and platform-independent.

The STEP 1 trial, published by Wilding et al. in the New England Journal of Medicine in 2021, randomized 1,961 adults with obesity or overweight to semaglutide 2.4 mg weekly or placebo. Over 68 weeks, participants receiving semaglutide lost an average of 14.9 percent of their body weight compared to 2.4 percent in the placebo group. This landmark trial established semaglutide as one of the most effective pharmaceutical interventions for weight management ever studied, with efficacy far exceeding older weight loss medications.

The SURMOUNT-1 trial, published by Jastreboff et al. in the New England Journal of Medicine in 2022, evaluated tirzepatide in 2,539 adults with obesity. The highest dose group (15 mg weekly) achieved an average weight reduction of 22.5 percent of body weight over 72 weeks — the largest average weight loss ever observed in a pharmaceutical obesity trial. Tirzepatide's dual mechanism as both a GIP and GLP-1 receptor agonist appears to produce additive metabolic benefits beyond what GLP-1 stimulation alone achieves.

These results apply equally whether the medication comes from Hims, Henry Meds, Trimi, or any other legitimate provider prescribing the same active ingredients at the same doses. The compounded versions of semaglutide and tirzepatide contain the identical active pharmaceutical ingredient as the brand-name products studied in these trials. What a good provider adds is not better medication — the medication is the same — but better clinical guidance on dose titration, side effect management, and long-term treatment strategy.

Where Hims Has the Edge

Where Henry Meds Has the Edge

Shared Limitations of Both Platforms

Why Trimi Compares Favorably to Both

For patients whose primary criteria are effective GLP-1 medication at the lowest sustainable price with quality clinical support, Trimi addresses the key cost and specialization gaps in both the Hims and Henry Meds models. At $99 per month for compounded semaglutide and $125 per month for compounded tirzepatide, Trimi's everyday pricing undercuts both competitors without requiring promotional codes, multi-month commitments, or limited-time offers.

The annual savings are substantial. A patient taking semaglutide for 12 months saves $600 to $1,200 compared to Hims and $1,200 to $3,000 compared to Henry Meds by choosing Trimi. For tirzepatide, the annual difference is even greater — up to $3,888 in savings compared to Henry Meds' highest tier. For patients considering switching from either platform, our guides on switching from Hims and Trimi vs Henry Meds walk through the transition process.

The Bottom Line

Hims and Henry Meds are both legitimate telehealth platforms prescribing real GLP-1 medications through licensed providers. If you are choosing only between these two, Hims generally offers better value due to lower semaglutide pricing, no separate consultation fee, and the operational stability of a publicly traded company. Henry Meds may appeal to patients who prefer its more focused weight loss positioning and potentially more interactive consultation model, despite the higher price point.

However, both platforms are more expensive than necessary for the same active medications. Trimi offers compounded semaglutide at $99 per month and compounded tirzepatide at $125 per month — with no consultation fees, no contracts, and providers who specialize in metabolic health. Over a 12-month treatment course, the cumulative savings are significant enough to matter for most patients' budgets. The medication produces the results, not the brand on the shipping label. Choose the provider that gives you the best combination of affordable pricing, clinical support, and treatment flexibility for the long term.

We encourage patients to verify current pricing directly on each platform's website before committing. Compare total annual cost at your expected maintenance dose, not introductory prices at the lowest dose. For a broader view of the GLP-1 provider landscape, see our best GLP-1 provider guide and our cheapest GLP-1 providers ranking.